Search this site

Oil stocks led Monday’s market rally as investors assessed the potential reopening of Venezuelan oil markets. The S&P 500’s energy sector climbed 2.7 percent, helping the broader index gain 0.6 percent, with refiners and oil service companies seeing the largest jumps. Valero Energy Corporation surged 9.2 percent, poised to benefit from heavier Venezuelan crude, while SLB Limited, the oil services giant, rose 9 percent on expectations for renewed extraction and infrastructure projects. Chevron, which has maintained operations in Venezuela, added 5.1 percent, and ConocoPhillips and Exxon Mobil, still owed funds from the nationalization of foreign assets, also posted gains. The rally follows recent geopolitical moves in Venezuela that have prompted speculation about U.S. oil companies returning to one of the world’s largest proven oil reserves. Analysts note that while Venezuela produces only about 1 percent of global oil, unlocking its reserves could provide long-term production upside for American firms. Investors initially worried that aggressive actions in Venezuela might destabilize global markets or encourage military conflicts elsewhere, such as in Asia. “I think the market has concluded that the geopolitical consequences won’t be as significant or as stunning as the action has been,” noted president of Yardeni Research, Edward Yardeni. Oil prices also responded to the developments, with Brent crude rising 1.7 percent to $58.32 per barrel. While increased Venezuelan production could ultimately exert downward pressure on oil prices in an already well-supplied market, some investors see short-term opportunities in refiners and service providers. As we noted in December 2025, energy appears to be gradually returning to core diversified portfolios, supported by improving earnings and strategic geopolitical positioning.

The global mining and metals landscape is heading into 2026 with cautious optimism, according to a new outlook from BMI, a unit of Fitch Solutions. While lingering weakness in Mainland China’s property sector continues to cap upside for base metals, tighter supply conditions and sustained demand from decarbonization-linked industries are expected to push most mineral and metal prices modestly higher. BMI frames the coming year as a balancing act. On one side are easing tariff uncertainties and structural demand tied to energy transition technologies. On the other are macro headwinds from China, where the property downturn remains a drag on bulk and base metal consumption, limiting how far prices can run even as supply constraints persist. Gold is expected to average higher in 2026 than in 2025, BMI says, supported by lingering geopolitical risk and still-accommodative monetary conditions. However, the firm flags a potential softening later in the year as global easing cycles mature and the U.S. Federal Reserve brings rate cuts to an end. Industrial Policy Takes Center Stage According to BMI, industrial policy will remain the primary lever for securing critical minerals in 2026. The U.S. and EU are expected to intensify efforts to expand domestic mining and processing capacity, while simultaneously locking in overseas supply through strategic investments, partnerships, and long-term offtake agreements. China, meanwhile, is unlikely to relinquish its grip on critical mineral value chains. BMI expects Beijing to accelerate exploration, expand capacity in batteries and rare earths, and push greener manufacturing while deepening ties with resource-rich nations under clearer outbound investment rules. Recent tariffs and rare earth export controls underscore that protectionist tools will remain firmly in play. M&A Stays Strong Competition for energy transition materials is set to keep merger and acquisition activity elevated into 2026. BMI notes that miners will continue to prioritize exposure to copper, lithium, and rare earth elements, viewing these assets as strategically indispensable. Large capital projects remain on the table, but the preference is shifting toward phased developments and brownfield expansions as companies navigate cost inflation and policy uncertainty. BMI also sees sustained investment flowing into frontier markets next year, despite rising concerns around resource nationalism. Governments and local communities—especially across Africa—are increasingly aware of the strategic value of their mineral endowments. As bargaining power shifts, miners will have limited room to push back against evolving fiscal and regulatory frameworks. A Strategic Year Ahead Partnerships between mining projects and downstream players in technology, automotive, aerospace, and defence are expected to deepen. BMI highlights that supply bottlenecks now pose real risks to growth in AI, robotics, and defence manufacturing, incentivizing end-users to secure materials directly at the mine level. Taken together, BMI’s outlook suggests that 2026 will be less about runaway commodity prices and more about positioning. Industrial policy, geopolitical competition for critical minerals, and shifting power dynamics in frontier markets are set to dictate where capital flows next, reshaping the global mining industry in the process.

Artificial intelligence investment remains one of the most durable growth themes in the global economy. According to the Organisation for Economic Co-operation and Development (OECD), spending on AI is expected to keep rising, even as broader economic conditions soften and trade uncertainty lingers. The Paris-based institution recently upgraded forecasts for several major economies, including the U.S., noting that technology investment is already helping offset external pressures. AI, in particular, is emerging as a stabilizing force at a time when traditional growth drivers face headwinds. OECD Secretary General Mathias Cormann said the momentum behind AI investment is far from peaking. In comments to Bloomberg Television, he explained, “We do expect that the level of investment in relation to AI will continue to increase for some time,” adding, “Over the medium- to long-term, we do expect a significant beneficial impact when it comes to productivity growth from the accelerating diffusion and adoption of AI across the economy.” As AI tools diffuse more broadly through supply chains, services, and manufacturing, efficiency gains could help counter slower labor growth and rising input costs. That optimism, however, is tempered by a more cautious macro outlook. The OECD expects global economic growth to slow to 2.9% next year, from 3.2% in 2025. Trade-related risks remain elevated, with tariffs and policy uncertainty yet to be fully reflected in economic data. Cormann warned that downside risks are still material. “The impact of tariffs are yet to be fully felt and there is a continued level of trade uncertainty and a whole range of other structural pressures.”

For the first time in years, investors are giving oil and gas producers another look. Years of underperformance left energy stocks sitting out much of the market’s rally. The S&P 500 Energy Index is up around 4% since 2022, while the S&P 500 has climbed nearly 80%. Range-bound oil prices and years of underperformance kept buyers on the sidelines. And as tech stocks face selling pressure, energy is suddenly one of the market’s cheapest and intriguing opportunities. A Sector Investors Are “Kicking the Tires” On Analysts point to valuation first. Energy is now the lowest-priced sector in the S&P 500 on a forward earnings basis, a compelling setup for investors searching for diversification outside AI and software. Adam Turnquist, vice president and chief technical strategist at LPL Financial, says clients are beginning to revisit the group. “People are kicking the tires on this sector now, they’re looking for diversification outside of AI,” he noted, adding that energy is breaking through key technical levels with market-leading breadth. “There’s more upside than expected.” The shift didn’t happen overnight. Energy stocks have rallied 19% since their April 8 low, with 77% of S&P 500 energy companies now trading above their 200-day average. While that would normally be a sign of overheating, the sector’s long-term sluggishness softens the signal. This is still a recovery, not a peak. In the November pullback when tech and other momentum names were hit hardest, money flowed into value plays. The State Street Energy Select Sector Fund (XLE) saw its first net inflow in a year and its largest since mid-2024. Quiet as it may be, energy has been the second-best performer of all 11 S&P sectors over the last two months. Matt Maley, chief market strategist at Miller Tabak + Co., believes the recent performance deserves more attention. “After two months, people need to pay attention,” he said, noting that Exxon Mobil’s latest guidance shows that even with oil stuck near $50–$60, major producers continue to generate enormous cash flow. “It’s over hated and underweighted.” Still, some analysts remain caution on the longer-term outlook, especially for oil. Stacey Morris, head of energy research at VettaFi, notes, “People are still very cautious into 2026, given a really bearish outlook for oil – it seems like we’re still going to have this supply overhang,” But Morris is more upbeat on natural gas. Gas-tracking ETFs have seen four straight months of positive inflows, the strongest streak since 2022, supported by improving commodity prices and rising investor interest. This divergence between oil and gas outlooks could shape where energy-sector capital flows next. Is the Sector Ready for an Upgrade? Strategists are not rushing to raise their views just yet, noting that fundamentals will need to strengthen for the rally to carry much further. Hugo Ste-Marie of Scotiabank said in a recent note that “fundamentals will have to get better for the rally to extend much longer.” Still, sentiment is shifting. LPL Financial’s Turnquist raised energy to “neutral” earlier this year after a multi-year underweight stance, saying “we’re becoming increasingly optimistic.” If earnings improve and cash flows remain strong, energy may finally stage a comeback in core portfolios.

The UK and the US have struck a deal that guarantees zero tariffs on British pharmaceuticals shipped to America for the next three years. Under the terms, the UK will raise the price threshold for new treatments and increase overall NHS spending on medicines from 0.3% of GDP to 0.6% over the next decade. In return, US import taxes on UK-made drugs will remain at zero, protecting a key export worth at least £5 billion a year. Business and Trade Secretary Peter Kyle called it a “guarantee that UK pharmaceutical exports will enter the US tariff free, protecting jobs, boosting investment and paving the way for the UK to become a global hub for life sciences.” This zero-tariff deal follows repeated threats fromPresident Donald Trump to impose tariffs of up to 100% on branded drug imports. US officials argued that American consumers were effectively subsidizing the cost of medicines for other developed nations and sought to bring more production stateside. NICE, the UK’s advisory body, expects three to five additional medicines a year to be approved, potentially raising costs by around £3 billion. While some see this as a necessary investment in innovation, others, like Sally Gainsbury from the Nuffield Trust think tank, warn it’s “bad news” given budget restraints. “The extra cost will need to be fully-funded by the Treasury,” she said, adding that stretched budgets may be better spent on GP services or reducing hospital backlogs. Pharmaceutical investment in the UK has seen turbulence recently. GSK, Merck, and AstraZeneca all shifted focus to the US, pausing or cancelling UK expansions. This deal could reverse that trend: Bristol Myers Squibb has already indicated it could invest over $500 million in the UK over the next five years in research, development, and manufacturing. William Bain from the British Chambers of Commerce called the deal “a real win,” highlighting its potential to boost exports, investment, and the UK’s competitive position in global life sciences. For investors, this agreement signals stability in UK pharmaceutical exports to the US and could create a more predictable environment for both domestic and international pharma companies. With the UK bolstering its life sciences sector, potential openings in manufacturing, R&D, and supply chain investments are starting to take shape.

Bitcoin has taken a heavy hit, falling almost 30% from its October high. That kind of decline usually sparks the same question: is this finally the dip worth buying? Right now, the answer might still be no. According to one valuation framework, the market is still pricing Bitcoin well above its estimated fair value. This conversation circles back to Metcalfe’s Law, a framework that links the value of a network to the number of people using it. Claude Erb, a former commodities portfolio manager at TCW Group, has been applying the idea to Bitcoin for years. In simple terms, he uses the total number of bitcoins mined as a stand-in for user count, then projects what the asset should be worth. Erb is the first to admit this method is not perfect. Some investors own multiple coins, others hold tiny fractions, and plenty of bitcoins have disappeared forever. Still, he believes the model does something valuable. It creates what he calls a “conversational anchor”, a reference point that cuts through hype cycles and shifting narratives. Based on the model, Bitcoin’s fair value sits around $53,000. Today’s price is about $33,000 above that. The spread sounds extreme, but historically Bitcoin has wandered much further away from its fair value. Over the past five years, the price-to-value ratio has climbed as high as 3.2 and sunk as low as 0.4. Even earlier this year, when Bitcoin crossed $100,000, the ratio peaked at only 2.4. That means the rally did not break any historical patterns. The recent selloff has pulled the ratio down to roughly 1.6, yet that is still comfortably above levels that historically signaled strong long term entry points. So for investors scanning the market for a flashing buy signal, the takeaway is clearer now. A correction does not automatically create value. And while Bitcoin’s slide has been steep, the model suggests buyers may still be paying a premium. For now, the Metcalfe lens offers useful perspective. It is a reminder that price action and real network strength do not always move in sync. Even Erb acknowledges the model has flaws, yet he also notes that a valuation framework does not need to be flawless to help investors separate noise from signal.

Uranium production in the United States has been volatile for decades, but the revival is here. A combination of renewed push for nuclear energy driven by data center demand and bipartisan energy-security initiatives has elevated uranium to the center of U.S. critical mineral discussions. Uranium fuels roughly 20% of U.S. electricity via nuclear power plants and plays a key role in national defense, making it strategically important of strengthening domestic supply. Domestic production currently sits around 150,000 pounds per month, far from historical highs, yet meaningful as the U.S. seeks to rebuild its nuclear fuel capabilities. Production remains concentrated in Utah, Wyoming, and Arizona. Despite strong activity, the U.S. supplies less than 5% of its own uranium needs. American reactors require roughly 50 million pounds of uranium annually, leaving the bulk sourced from Kazakhstan, Canada, and Australia. This persistent shortfall has become more concerning as geopolitical pressures rise and global competition for supply tightens. New federal directives aim to narrow the gap, but rebuilding domestic capacity will take time. Government Policy Is Reshaping the Industry The U.S. government has officiallyadded uranium back to the nation’s list of critical minerals. Executive orders and funding initiatives now support ramped-up production, including $3.5 billion under the Defense Production Act and $500 million specifically for HALEU. Proposed tariffs on Russian uranium imports and streamlined permitting in states like Utah give producers clearer pathways to bring projects online. Nuclear energy has also gained rare bipartisan backing. Policymakers across party lines recognize uranium’s importance for reliable baseload power, data centre energy needs, and carbon reduction targets. This alignment has improved regulatory stability, shortened permitting timelines, and given producers more confidence to plan new projects. Challenges Facing U.S. Uranium Producers Current spot prices hover around $76-82 per pound, still below the $100 per pound many experts cite as the minimum for broad new-mine viability. There has been stabilization from 2024 peaks above $100, buoyed by utility contracting and funds like Sprott’s 2.3M-pound Q3 purchases. Costs have risen due to exploration, labour shortages, regulatory compliance, and reclamation obligations. Producers are facing logistical constraints such as trucking shortages, workforce retirements, and variable ISR recovery rates. ISR formations can see 30–40% recovery loss in complex geology, while conventional mining faces higher upfront capital burdens. New technologies like ore sorting, which can cut haulage costs by 50%, are improving efficiency but not eliminating bottlenecks. Even with recent improvements, permitting uranium mines remains a lengthy undertaking involving federal, state, local, and tribal reviews. Outlook for U.S. Uranium Mining Domestic uranium production shows signs of steady recovery, supported by a mix of policy, technology, and market factors. While European countries remain focused on transforming their energy mix, the US is increasingly prioritising nuclear security. The Department of Defense has set a procurement target of 10 million pounds of uranium between 2025 and 2030, an anchor for future demand. Technological improvements, such as ore sorting and digital twin mining, are increasing efficiency and lowering costs. The U.S. uranium industry is stronger than it has been in years. With nuclear energy gaining unprecedented political and strategic support, domestic producers are well-positioned to capitalize on rising demand and supply constraints, creating compelling opportunities to watch closely.

The historic shutdown may be over, but the government shutdown market impact is proving more disruptive than expected. Rather than rally on reopening news, markets saw their sharpest drop in a month as investors grew uneasy about AI valuations and rising uncertainty around monetary policy. Major indices pulled back decisively. The S&P 500 fell 1.7%, while the Dow Jones Industrial Average dropped 798 points, sliding back toward 47,000 just a day after breaching 48,000 for the first time. The Nasdaq Composite, heavily weighted toward high-growth tech stocks, led the declines with a 2.3% drop. This retreat signals markets are recalibrating after months of AI-driven enthusiasm. “We’re seeing a classic rotation under way,” said David Miller, chief investment officer and senior portfolio manager at Catalyst Funds. “Investors are taking some profits in megacap tech after an extended AI driven run and reallocating toward more reasonably valued sectors.” The shift marks a cooling in the year’s most crowded trade as investors reassess risk heading into the final weeks of 2025. The shutdown’s lingering effects are adding to the pressure. After more than 40 days without government data, economists warn that delayed releases could complicate the Federal Reserve’s next decision. “We anticipate ongoing challenges with obtaining a clean read – we think Q4 data will likely add more confusion than clarity,” wrote Mike Reid, senior U.S. economist at RBC. That uncertainty is now weighing on rate expectations, with the probability of a December cut slipping to roughly 52%. Quantum computing stocks also came under pressure, with D-Wave Quantum, Rigetti Computing, and IonQ all falling more than 10%. Benchmark analyst David Williams noted that “the recent volatility across emerging tech and AI sectors has tempered near-term investor enthusiasm,” even as companies continue to hit technical milestones. Mackenzie Tatananni, Barron’s quantum expert, explains: “Unlike traditional computers, quantum systems operate by the laws of quantum mechanics, which opens up a richer mathematical space for problem-solving.” She adds that quantum computing can streamline complex processes, from scientific modeling to drug discovery and machine learning. Recent developments in the sector highlight this potential. Rigetti shares rose for six straight days in October after announcing two purchase orders for its latest-generation Novera processor. Rival IonQ also reported a near-perfect score in a key reliability metric, enabling “practical quantum solutions across sectors.” Tech giant IBM unveiled its “most advanced quantum processor yet,” the Quantum Nighthawk, expected to reach customers by year-end. Despite near-term volatility, the long-term case for emerging tech and quantum computing remains intact. Investors now face a market reshaped by cooling AI valuations, delayed data, and uncertainty around Fed policy, a backdrop likely to keep volatility high through year-end.

Copper and silver are officially added to the U.S. expanded list of critical minerals, recognizing their indispensable role in America’s economy, technology, and defense infrastructure. The updated list now includes 60 minerals, up from 50 in 2022. Sources: Public Domain. According to the USGS, the updated list was created using a new economic model designed to estimate potential impacts from foreign trade disruptions. The assessment spanned 84 mineral commodities, 402 industries, and over 1,200 trade scenarios, producing what the agency calls a more “realistic and usable framework” for policymakers. Copper and Silver’s Strategic Role The inclusion of copper and silver has been widely applauded by industry leaders. “We strongly support USGS’s decision to add copper to the critical minerals list,” said Adam Estelle, President and CEO of the Copper Development Association (CDA). “Copper holds the key to achieving America’s top policy objectives—including energy dominance, AI supremacy, national security, and reindustrialization.” Copper, used in everything from electric vehicles and power grids to semiconductor wiring, is increasingly viewed as a linchpin of the clean energy transition. Silver is essential in solar panels, medical devices, and advanced electronics, further cementing its place as a vital industrial metal. Policy and Investment Implications The updated critical minerals list gives a roadmap for how the U.S. plans to secure its industrial future, and which materials could face Section 232 investigations, opening the door to potential tariffs or trade restrictions. We’ve already seen this play out with copper earlier in the year. Beyond waving red flags, it helps guide federal investments ranging from mining incentives and tax credits for recycling, to streamlined permitting for new projects. It will likely influence current stockpile programs and resource recovery efforts, ensuring the country is less dependent on foreign supply. This update comes right after Washington and Beijing reached an agreement to cool tensions over rare earth elements, which make up almost a quarter of the current list. It’s a reminder that America’s critical mineral strategy isn’t just economic – it’s geopolitical. At Wall Street Endeavor, we’ve been closely following the evolving U.S. strategy on critical minerals, especially as geopolitical and technological shifts continue to reshape global supply chains. We’ve been watching the skyrocketing fluorspar, featured in our articleTop Tip: Mining Multibagger, Ready to Run, which is vital for nuclear energy, li-ion batteries, and billion-dollar steel industries. Gallium is gaining attention for its role in high-efficiency electronics, including LEDs, smartphones, fiber optics, solar panels, and radar systems – yet the U.S. currently produces none of it. Meanwhile, palladium, a key metal for both clean energy and automotive innovation, has climbed to $1,260 per ounce, up from roughly $909 at the start of the year, driven by renewed industrial demand. For both miners and investors, the opportunity goes beyond short-term gains. With U.S. policy now tying resource development directly to industrial and energy priorities, projects in this space are benefiting from a convergence of strategic security and the push toward a cleaner, high-tech economy.

While Nvidia tends to dominate AI headlines, Broadcom has quietly built a powerful position behind the scenes. Its custom AI chips, networking solutions, and infrastructure software power some of the largest data centers in the world – from Google and Meta to OpenAI. Over the years, Broadcom has transformed from a chip supplier into a full-stack infrastructure player through a string of major acquisitions, including VMware and Symantec’s enterprise business. That mix of hardware and software now gives Broadcom a strong advantage as AI computing demand skyrockets. Numbers that caught Wall Street’s attention Broadcom’s latest quarterly results tell the story. Revenue hit $15.95 billion, up 22% year-over-year. Its semiconductor business grew 26%, and software revenue climbed 17%, fueled by the VMware integration. Free cash flow reached a record $7 billion, and the company returned nearly $3 billion to shareholders through dividends. Year-to-date, Broadcom stock is up roughly 55%, nearly doubling over the past twelve months, far outperforming the S&P 500’s 14% gain. That kind of momentum isn’t going unnoticed. Analysts are turning bullish Jefferies analysts led by Blayne Curtis recently raised Broadcom’s price target from $415 to $480, calling the company their “Franchise Pick” with “outsized upside.” The optimism centers on Broadcom’s custom AI accelerator business, which is gaining traction with hyperscalers. Google’s next-gen TPU chips, Meta’s in-house AI designs, and OpenAI’s expanding infrastructure could all translate into billions in new revenue for Broadcom. Jefferies now expects the company’s AI-related sales to hit $10 billion by 2027, and potentially $40–50 billion annually by 2028. Why it matters This offers a strong signal about where AI infrastructure spending is heading. The world’s biggest tech companies are racing to build faster, more efficient systems, and Broadcom is supplying key pieces of that puzzle. The takeaway Broadcom’s mix of strong fundamentals, growing AI exposure, and high-margin software gives it serious long-term potential. The company is already being recognized as one of the few tech leaders that can scale with the AI revolution – making it, in our opinion, a worthy endeavor for those seeking growth in the sector.

The Trump administration’s looming threat of a 100% tariff on imported branded and patented drugs has global drugmakers announcing splashy US investments. While enforcement may be delayed for companies investing in U.S. manufacturing, the policy has already prompted fast-tracked projects, price adjustments, and even direct-to-consumer sales. Here’s a look at what some of the biggest players are doing to mitigate supply-chain risks and reassure investors: Pfizer (PFE) Pfizer has committed $70 billion toward expanding its U.S.-based research, development, and manufacturing operations. The agreement secured a three-year grace period exempting its products from the potential tariffs, as the company accelerates domestic production and shifts inventories to mitigate risk. GSK (GSK.L) The London-based drugmaker is investing $30 billion over five years to expand its U.S. research and supply chain capabilities. GSK’s focus is on building long-term manufacturing resilience and reducing exposure to global trade disruptions. Eli Lilly (LLY) Eli Lilly announced a $5 billion investment to build a major manufacturing facility in Virginia, the first of four planned U.S. plants. The project forms part of a broader $27 billion, five-year expansion to strengthen domestic supply chains and support future product launches. Johnson & Johnson (JNJ) J&J is raising its U.S. investment by 25%, bringing its total to $55 billion over the next four years. The company is building four new plants, including sites in Wilson and Holly Springs, North Carolina, to boost capacity and support future biologics manufacturing. Roche (ROG.S) Roche plans to invest $50 billion in U.S. operations over the next five years, including a $550 million expansion at its Indianapolis diagnostics hub and a new facility in Holly Springs, NC. The expansions, spanning Indiana, Pennsylvania, Massachusetts, and California are expected to create more than 12,000 jobs. AstraZeneca (AZN.L) AstraZeneca is committing $50 billion to U.S. manufacturing by 2030, anchored by a new drug substance facility in Virginia, its largest global investment to date. Additional expansions in Maryland, Massachusetts, California, Indiana, and Texas will further strengthen its U.S. supply network. Novartis (NOVN.S) Novartis plans to spend $23 billion over the next five years to build and expand 10 U.S. facilities, including six new manufacturing plants and an expanded San Diego R&D site. The initiative is expected to create more than 1,000 new jobs and significantly boost its domestic output. Sanofi (SASY.PA) The French pharmaceutical giant has pledged at least $20 billion through 2030 to grow its U.S. manufacturing capacity. Sanofi is expanding both its company-owned sites and partnerships with domestic manufacturers to stay resilient amid shifting trade conditions. Biogen (BIIB.O) Biogen is investing $2 billion to expand its North Carolina operations, adding capacity for gene-targeting therapies and automation. The company will soon operate eight facilities in the state, positioning it as a leader in advanced biologics manufacturing. Merck (MRK.N) Merck is one of the largest spenders, with a $3 billion pharmaceutical plant under construction in Virginia and a $1 billion biologics facility in Delaware. Combined with new expansions in North Carolina and Kansas, the company’s total U.S. investment exceeds $70 billion, supporting more than 4,500 new jobs. AbbVie (ABBV.N) AbbVie is continuing a $10 billion U.S. expansion over the next decade. With 11 existing manufacturing sites, the company says it is “fairly insulated” from any near-term tariff impact thanks to proactive inventory management. Gilead Sciences (GILD.O) Gilead has announced $11 billion in new investment, bringing its total U.S. commitment to $32 billion. The company is building a pharmaceutical development and manufacturing hub in Foster City, CA, and developing two additional sites to expand its R&D footprint. For investors, the message is simple: big pharma isn’t waiting for tariffs to hit. They’re shifting cash and plants back to the U.S. to lock in growth and dodge risk. Earlier, Trump suggested tariffs could reach as high as 250%, but for now, these major branded-drug makers are clearly taking steps to stay ahead.

GE Aerospace is flying high. Shares of the jet-engine maker climbed 2.4% in early trading Tuesday, putting the stock on track to open above its September record close of $305.63. The boost comes after a quarter that didn’t just meet expectations, it blew them away. The company reported net profit of $2.52 billion for the quarter ending September 30, a jump of nearly 33% from a year ago. Adjusted earnings per share came in at $1.66, topping analyst expectations of $1.46. That 20-cent beat marked the largest earnings surprise in two years. Commercial Engines Drive Growth Revenue rose almost 24% year-over-year to $12.18 billion, easily beating the consensus of $10.94 billion. The real star was GE’s commercial engines segment, where sales soared 26.8% to $8.88 billion. Deliveries were up 33% overall, including a record 40% increase in LEAP engine shipments, proof that airlines are betting on GE’s technology to power the skies. Confident Outlook With these results in hand, GE raised its full-year EPS guidance to $6–$6.20, up from a prior range of $5.60–$5.80, surpassing analyst expectations of $5.90. Revenue growth forecasts were lifted to the high-teens, up from mid-teens. Free cash flow jumped 29.8% to $2.36 billion, the company’s strongest quarter since late 2023, giving investors even more confidence in GE’s financial health. Why Investors Are Taking Notice GE’s stock has climbed 81.5% year-to-date, compared with a 14.5% gain in the S&P 500. With solid deliveries, growing revenue, and serious cash flow, GE Aerospace is looking like a solid bet for anyone thinking long-term.